Author:
Kok Marleen,Zwart Wilbert,Holm Caroline,Fles Renske,Hauptmann Michael,Van’t Veer Laura J.,Wessels Lodewyk F. A.,Neefjes Jacques,Stål Olle,Linn Sabine C.,Landberg Göran,Michalides Rob
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Pritchard KI (2003) Endocrine therapy of advanced disease: analysis and implications of the existing data. Clin Cancer Res 9:460S–467S
2. O’Regan RM, Jordan VC (2002) The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol 3:207–214
3. Johnston SR, Dowsett M (2003) Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 3:821–831
4. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867–3873
5. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20:3386–3395